Agilent Technologies, Inc. - Diagnostics and Genomics SureSelectXT NCC oncopanel, 96 rxn
The SureSelectXT NCC Oncopanel from Agilent Technologies is a targeted next-generation sequencing (NGS) solution designed for comprehensive cancer research. This panel enables the detection of clinically relevant somatic variants across a broad range of cancer-related genes. The kit includes reagents for 96 reactions and is optimized for high sensitivity and specificity, supporting the identification of single nucleotide variants, insertions, deletions, and copy number variations. The SureSelectXT workflow is compatible with various sample types, including formalin-fixed, paraffin-embedded (FFPE) tissues, and integrates seamlessly with Agilent's bioinformatics tools for streamlined data analysis.